Quantification methods of amorphous/crystalline fractions in high-energy ball milled pharmaceutical products

Journal of Thermal Analysis and Calorimetry

Volumn 108, Issue 1, 2012, Pages 235-241

  Bruni, Giovanna ^a   Berbenni, Vittorio ^a   Sartor, Franco ^b   Milanese, Chiara ^a   Girella, Alessandro ^a   Franchi, Dionigio ^c   Marini, Amedeo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b Aptuit Inc   (United States)

^c GSK   (Italy)

Author keywords

Amorphous phase; Crystalline solids; DSC; Mechanical activation; Milling

Indexed keywords

AMORPHOUS PHASE; BALL-MILLED; BULK CRYSTALS; CRYSTAL ORDER; CRYSTALLINE CORE; CRYSTALLINE SOLIDS; DIFFRACTOMETRY; DSC; HIGH ENERGY; MECHANICAL ACTIVATION; MECHANICAL TREATMENTS; PHARMACEUTICAL PRODUCTS; QUANTIFICATION METHODS; SOLID-PHASE;

MECHANICAL ALLOYING; MILLING (MACHINING);

CRYSTALLINE MATERIALS;

EID: 84858069499     PISSN: 13886150     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10973-011-1504-y     Document Type: Article

References (22)

1. SR Vippagunta HG Brittain DJW Grant 2001 Crystalline solids Adv Drug Deliv Rev 48 3 26 10.1016/S0169-409X(01)00097-7 1:CAS:528:DC%2BD3MXivFejsrs%3D (Pubitemid 32452290)
2. Hilfiker R, Blatter F, Raumer M. Relevance of solid-state properties for pharmaceutical products. In: Polymorphism in the pharmaceutical industry. Weinheim: Wiley-VCH; 2006. p. 1-19.
3. A Marini V Berbenni G Bruni P Cofrancesco F Giordano M Villa 2003 Physico-chemical characterization of drugs and drug forms in the solid state Curr Med Chem 2 303 321 1:CAS:528:DC%2BD3sXptVGmsrw%3D
4. A Marini V Berbenni G Bruni C Margheritis A Orlandi 2001 Physicochemical study of the solid forms of a new drug J Pharm Sci 90 2131 2140 10.1002/jps.1164 1:CAS:528:DC%2BD3MXpt1Clsbc%3D (Pubitemid 33144458)
5. A Marini V Berbenni G Bruni A Maggioni P Cofrancesco C Sinistri A Orlandi M Villa 2003 Solid state characterization of a novel chemotherapeutic drug J Pharm Sci 92 577 584 10.1002/jps.10315 1:CAS:528:DC%2BD3sXitVWqu7s%3D (Pubitemid 36258972)
6. G Bruni V Berbenni C Milanese A Girella A Cardini E Viganò S Lanfranconi A Marini 2009 Thermodynamic relationship between nateglinide polymorphs J Pharm Biomed Anal 50 764 770 10.1016/j.jpba.2009.06.017 1:CAS:528:DC%2BD1MXhtF2ht7bE
7. G Bruni C Milanese G Bellazzi V Berbenni P Cofrancesco A Marini M Villa 2007 Quantification of drug amorphous fraction by DSC J Therm Anal Calorim 89 761 766 10.1007/s10973-006-7943-1 1:CAS:528:DC%2BD2sXpvVCisbY%3D (Pubitemid 47351769)
8. L Yu 2001 Amorphous pharmaceutical solids: preparation, characterization and stabilization Adv Drug Deliv Rev 48 27 42 10.1016/S0169-409X(01)00098-9 1:CAS:528:DC%2BD3MXivFejsrg%3D (Pubitemid 32454482)
9. JF Willart A De Gusseme S Hemon G Odou F Danede M Descmps 2001 Direct crystal to glass transformation of trehalose induced by ball milling Solid State Commun 119 501 505 10.1016/S0038-1098(01)00283-6 1:CAS:528:DC%2BD3MXlsFynur0%3D (Pubitemid 32719788)
10. HG Brittain 2002 Effects of mechanical processing on phase composition J Pharm Sci 91 1573 1580 10.1002/jps.10115 1:CAS:528:DC%2BD38XltVyit7Y%3D (Pubitemid 34680220)
11. AA Elamin T Sebhatu C Ahlneck 1995 The use of amorphous substances to study mechanically activated materials in the solid state Int J Pharm 119 25 36 10.1016/0378-5173(94)00364-B 1:CAS:528:DyaK2MXkvFGqt7o%3D
12. G Bruni C Milanese V Berbenni F Sartor M Villa A Marini 2010 Crystalline and amorphous phases of a new drug J Therm Anal Calorim 102 297 303 10.1007/s10973-009-0614-2 1:CAS:528:DC%2BC3cXhtFartLzJ
13. R Hutternrauch 1983 Modification of starting materials to improve tabletting properties Pharm Ind 45 435 440
14. B Hancock G Zografy 1997 Characteristics and significance of the amorphous state in pharmaceutical systems J Pharm Sci 86 1 12 10.1021/js9601896 1:CAS:528:DyaK28XntlOqt7k%3D
15. AA Elamin C Ahlneck G Alderborn C Nystrom 1994 Increased metastable solubility of milled griseofulvin, depending on the formation of a disordered surface structure Int J Pharm 111 159 170 10.1016/0378-5173(94)00132-4 1:CAS:528:DyaK2cXmtlyhtbg%3D (Pubitemid 24288892)
16. B Hancock M Parks 2000 What is the solubility advantage for amorphous pharmaceuticals Pharm Res 17 397 404 10.1023/A:1007516718048 1:CAS:528:DC%2BD3cXktFalsb0%3D (Pubitemid 30395293)
17. NM Vemuri Z Chrzan R Cavatur 2004 Use of isothermal microcalorimetry in pharmaceutical preformulation studies Part II. Amorphous phase quantification in a predominantly crystalline phase J Therm Anal Calorim 78 55 62 10.1023/B:JTAN.0000042153.17228.84
18. M Lappalainen I Pitkanen 2006 Quantification of amorphous content in maltitol by StepScan DSC J Therm Anal Calorim 84 345 353 10.1007/s10973-006- 7520-7 1:CAS:528:DC%2BD28XksFektbs%3D (Pubitemid 43724288)
19. ST Charlton J Whetstone ST Fayinka KD Read L Illum SS Davis 2008 Evaluation of direct transport pathways of glycine receptor antagonists and an angiotensin antagonist from the nasal cavity to the central nervous system in the rat model Pharm Res 25 1531 1543 10.1007/s11095-008-9550-2 1:CAS:528:DC%2BD1cXmslWntbg%3D
20. C Heidbreder 2005 Recent advances in the pharmacotherapeutic management of drug dependence and addiction Curr Psychiatry Rev 1 45 67 10.2174/1573400052953538 1:CAS:528:DC%2BD2MXisVagur8%3D
21. J Kerč S Srčič 1995 Thermal analysis of glassy pharmaceuticals Thermochim Acta 248 81 95 10.1016/0040-6031(94)01949-H
22. I Alig D Braun R Langendorf M Voigt JH Wendorff 1997 Simultaneous ageing and crystallization process within the glassy state of a low molecular weight substance J Non-Cryst Solids 221 261 264 10.1016/S0022-3093(97)00428-6 1:CAS:528:DyaK2sXotVyiurs%3D (Pubitemid 127433551)